Gilead Sciences Inc. (NASDAQ:GILD) Deals with its HCV Drug Issue

Gilead Sciences Inc. (NASDAQ:GILD) Deals with its HCV Drug Issue Gilead Sciences Inc. (NASDAQ:GILD) has taken the decision to limit the number of patients it admits to its support path patient assistance program. The decision only affects those patients seeking … Continue reading

Gilead Sciences, Inc. (GILD) Leads The HCV Race Despite Competition From

Gilead Sciences, Inc. (GILD) Leads The HCV Race Despite Competition From … AbbVie launched its hepatitis C drug, Viekira Pak, with the intent to cannibalize Gilead's hepatitis C drug sales, as evident from the fact that the company immediately went … Continue reading